Novartis’ Kisqali (ribociclib) + Fulvestrant Receive NICE Approval for Advanced or Metastatic Breast Cancer

Novartis’ Kisqali (ribociclib) + Fulvestrant Receive NICE Approval for Advanced or Metastatic Breast Cancer

Shots:

  • The NICE approval is based on P-III MONALEESA-3 study results assessing Kisqali + fulvestrant vs fulvestrant as monothx. in patients with HR+/HER2- LA or metastatic breast cancer prior treated with endocrinal therapy
  • The P-III MONALEESA-3 study results: mPFS (20.5 mos. vs 12.8 mos.); 2L post-menopausal patients, mPFS (14.6 mos. vs 9.1 mos.)
  • Kisqali is a CDK4/6 inhibitor and is an approved therapy in the US and EU for breast cancer, will be available on the Cancer Drugs Fund (CDF) following its approval by NICE published in the draft guidance

Click here to read full press release/ article | Ref: NICE | Image: The Business Journals